Safety of intermediate dose of low molecular weight heparin in COVID-19 patients

Coagulopathy represents one of the most important determinants of morbidity and mortality in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or higher doses are needed, especially in severe patients, is unknown. To evaluate the safety of intermediate dose regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattioli, Massimo, Benfaremo, Devis, Mancini, Mauro, Mucci, Luciano, Mainquà, Paola, Polenta, Antonio, Baldini, Patrizia Maria, Fulgenzi, Francesca, Dennetta, Donatella, Bedetta, Samuele, Gasperoni, Lorenzo, Caraffa, Alessandro, Frausini, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426007/
https://www.ncbi.nlm.nih.gov/pubmed/32794132
http://dx.doi.org/10.1007/s11239-020-02243-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426007/
https://www.ncbi.nlm.nih.gov/pubmed/32794132
http://dx.doi.org/10.1007/s11239-020-02243-z

Ejemplares similares